BTK Inhibitor Tolebrutinib: Breaking the Silent Progression of Multiple Sclerosis

Multiple sclerosis (MS), a chronic autoimmune disease affecting over 1.8 million people worldwide, has long faced a treatment gap for its nonrelapsing secondary progressive form (SPMS). Even without relapses, these patients continue to experience ongoing neurological deterioration, and traditional anti-relapsing drugs have limited efficacy, creating a clinical pain point that urgently needs to be addressed.

Recently published data from the Phase 3 HERCULES clinical trial in the New England Journal of Medicine offer a breakthrough for the industry. A study of 1,131 patients with nonrelapsing SPMS showed that the oral BTK inhibitor tolebrutinib reduced the risk of sustained disability progression by 31% over six months and outperformed placebo in terms of MRI lesion reduction, improved gait stability, and disability improvement rate. This drug's key advantage lies in its ability to cross the blood-brain barrier and directly inhibit B cell and microglial activity in the central nervous system, targeting "chronic latent neuroinflammation"—a key mechanism of disability progression—and addressing the shortcomings of traditional drugs that only control relapses.

This breakthrough not only makes tolebrutinib the first oral BTK inhibitor to demonstrate efficacy in nonrelapsing SPMS, but also reshapes the treatment paradigm for MS: It demonstrates for the first time that active intervention with chronic inflammation can delay disease progression, even in the absence of relapses. However, it is important to note that this drug carries the risk of liver dysfunction, necessitating enhanced ALT monitoring during clinical use. In the future, BTK inhibitors with high central penetration may become a mainstream treatment for progressive MS, providing a new benchmark for industry research and development and clinical practice.